NISIT RAWO
- 2seventy bio (NASDAQ:TSVT) traded higher premarket Thursday after announcing the completion of an asset purchase agreement under which Novo Nordisk (NVO) (OTCPK:NONOF) has acquired its Hemophilia A program and rights to certain other assets.
- The staff members working in the program will also join the pharma giant as part of the deal, the company said in a press release late Wednesday.
- In addition to the Hemophilia A program, the Danish drugmaker will receive rights to 2seventy bio’s (TSVT) certain gene editing technology that targets autoimmune diseases.
- In return, the developer of Bristol Myers’ (BMY)-partnered CAR T cell therapy Abecma is eligible to receive payments worth up to $40M.
- 2seventy Bio (TSVT) said the deal would help improve its focus on commercialization and further research into abecma, which is indicated for multiple myeloma in the U.S.